The future of preventive medicine starts here
Our mission is to develop targeted live biotherapeutics and molecular diagnostic tools that target the core drivers of diseases of high unmet medical need
See Our Pipeline
Developing better therapies through a deep understanding of human microbial ecology
As a leading developer of next-generation live biotherapeutic products, we combine clinical data, bioinformatics, and top-notch microbial science to develop synergistic combinations of bacteria that target diseases with high unmet medical need. By leveraging our proprietary Precision Symbiotics Platform™ and in-house GMP manufacturing capabilities, we have rationally designed microbial consortia to address medical conditions where the human microbiota plays a central role in disease prevention.
Our Platform

News
Siolta Therapeutics and Cowellnex Enter Joint Research Agreement
January 29, 2025
Read More

News
Nexilico and Siolta Therapeutics Enter Collaboration Agreement to Address Necrotizing Enterocolitis
September 17, 2024
Read More

News
Microbiome Times Partnering Forum
Dr. Nikole Kimes Joins the Conference’s Opening Panel: The Present and Future of the Microbiome Industry
March 18, 2025
Read More